Exelixis (EXEL) UBS Global Biopharma Conference 2026 summary
Event summary combining transcript, slides, and related documents.
UBS Global Biopharma Conference 2026 summary
17 Nov, 2026Strategic transition and priorities
Transitioning from a CABOMETYX-centered business to a multi-franchise model, with potential zanzalintinib approval and a PDUFA date expected early next year.
Near-term priorities include sustaining CABOMETYX performance, advancing zanzalintinib development and pre-commercial work, and maintaining early-pipeline investment and expense discipline.
Seven pivotal zanzalintinib studies make up wave one; a second wave could offer larger opportunities, with a frontline RCC study expected to anchor it.
CABOMETYX and RCC market dynamics
LITESPARK-011 showed a PFS benefit but no statistically significant OS advantage; sequencing versus combination, tolerability and treatment duration remain considerations for patients and physicians.
Increased use of lenvatinib/belzutifan in second line could shift some lenvatinib use away from first line; first-line share gains may partly offset second-line share pressure.
LITESPARK-012's failure creates an opportunity to invest in frontline RCC; the frontline study is among the key wave-two zanzalintinib opportunities.
Development is aimed at future RCC treatment pathways, including more patients receiving adjuvant pembrolizumab; LITESPARK-033 targets the post-adjuvant frontline setting and LITESPARK-034 a later-line setting.
Management views CABOMETYX as the TKI of choice for the 2020s and zanzalintinib as the potential TKI of choice for the 2030s.
NET opportunity and CABOMETYX commercial factors
The second-line-or-later oral NET market is estimated at $1B; management said the aspirational peak-sales goal remains unchanged, while the indolent disease can delay treatment starts and shift the launch curve.
NET market-share and patient-share data indicate uptake; management aims to capture share across the market, supported by CABINET data and high share of voice in a largely generic market.
340B-related sales variability reflects industry and seasonal dynamics; annual, rather than quarterly, guidance is intended to reflect results over the full year.
Business planning uses January 1, 2031 as the best estimate for generic CABOMETYX availability; legal challenges are being managed as they arise.
Latest events from Exelixis
- Zanza’s seven pivotal trials anchor a disciplined shift toward multiple franchises.EXEL
Jefferies Global Healthcare Conference - Zanzalintinib’s 2027 milestones anchor a broader, multi-franchise growth strategy.EXEL
Stifel 2026 Healthcare Conference 2026 - CABO growth funds a broad zanza pipeline while R&D, BD and buybacks remain concurrent priorities.EXEL
3rd Annual Guggenheim Healthcare Innovation Conference - Revenue rose 10% as cabozantinib grew and zanzalintinib advanced; CRC review targets 2027.EXEL
Q3 2026 - Zanzalintinib’s pivotal pipeline and CRC launch plans anchor a multi-franchise growth strategy.EXEL
Morgan Stanley 24th Annual Global Healthcare Conference - Q4 revenue rose 13% as CABOMETYX expansion and pipeline growth shaped 2024 priorities.EXEL
Q4 2023 - CABOMETYX and zanzalintinib drive growth across oncology franchises, with AI boosting efficiency.EXEL
Citigroup’s Biopharma Back to School Summit 2026 - CABO and zanza drive growth, with immediate CRC launch readiness and robust pipeline plans.EXEL
Wells Fargo 21st Annual Healthcare Conference - Q2 2026 revenue rose 11% to $629M, with strong cabozantinib sales and zanzalintinib NDA review.EXEL
Q2 2026